Management of Type 2 Diabetes

15
Management of Type 2 Diabetes New Zealand Guidelines Group

description

Management of Type 2 Diabetes. New Zealand Guidelines Group. Cost of Type 2 Diabetes. Major component of General Practice work requiring an intensive and integrated approach: 2010 prevalence: 195,778 people with type 2 diabetes or 4.4% of New Zealanders 50-64: 8-9%, 65+: 15-16% - PowerPoint PPT Presentation

Transcript of Management of Type 2 Diabetes

Page 1: Management of Type 2 Diabetes

Management of Type 2 Diabetes

New Zealand Guidelines Group

Page 2: Management of Type 2 Diabetes
Page 3: Management of Type 2 Diabetes

Cost of Type 2 Diabetes

1. Major component of General Practice work requiring an intensive and integrated approach:

2. 2010 prevalence: 195,778 people with type 2 diabetes or 4.4% of New Zealanders

I. 50-64: 8-9%, 65+: 15-16%

II. Number 4 OECD

3. Increased prevalence amongst Māori, Pacific and Indian subcontinent peoples

Page 4: Management of Type 2 Diabetes

Cost of Type 2 Diabetes cont.

4. An additional $3,721 of publicly funded health care for each person with type 2 diabetes per year1

5. Approximately $728 million extra healthcare cost per year

1. Ministry of Health, 2008

Page 5: Management of Type 2 Diabetes

Lead Role for General Practice

Many cases of type 2 diabetes ‘fall’ between General Practice and speciality care:

• Specialty services cannot effectively deal with existing burden

• General Practice have an increasingly important role in management

Page 6: Management of Type 2 Diabetes

Critical Issue: Management of BP

1. BP is measured frequently but BP targets set in clinical guidelines not being consistently met

2. Recent NZ reports indicate 53–78% of people with type 2 diabetes have a BP above 130/80 mm Hg

3. Key reasons are medication adherence by patients and clinical inertia, ie, failure of health practitioners to initiate or intensify treatment when indicated

Page 7: Management of Type 2 Diabetes

Blood pressure management

• Step wise approach: Multiple Medication

• Target BP <130/80 mm Hg

• Evidence suggests BP target <120 mm Hg may be harmful (ACCORD Study)

Page 8: Management of Type 2 Diabetes

Management: microalbuminuria

• People with confirmed microalbuminuria should be treated with an ACE inhibitor or ARB whether or not hypertension present

Page 9: Management of Type 2 Diabetes

Critical Issue: Risk of Complications

1. Preventing complications an important aspect of care

2. Every patient with type 2 diabetes should be assessed for risk of diabetes-related complications early in their diabetes care

3. Māori and Pacific – complications develop more frequently and at a younger age

Page 10: Management of Type 2 Diabetes

Focus: Risk of Complications

3. ‘Risk chart’ categorises into low, moderate or high risk for diabetes-related complications:• Two identified risk factors places person at

moderate risk

• Three identified risk factors is assessed as high risk

• An ‘existing’ complication (eg, previous cardiac event) places person at high risk.

Page 11: Management of Type 2 Diabetes

Focus: Risk of Complications

• Two identified risk factors (eg. HbA1c >55 mmol/mol (~ 7%), and eGFR <60 ml/min/1.73m2 is at moderate risk

• Three identified risk factors (eg, HbA1c >55 mmol/mol, eGFR <60 ml/min/1.73m2 plus BP >130/80 mm Hg) is at high risk for complications

Page 12: Management of Type 2 Diabetes

Key Points For General Practice(1)

1. General Practice and Primary Care need to take the lead

2. Identify risk of complications early for intensive intervention

Page 13: Management of Type 2 Diabetes

Key Points (2)

3. Aim for HbA1c 50–55 mmol/mol (~7%)

I. Not too aggressive target 7%(50-55)

II. Accord (2010) – Some evidence increase fatal events with tighter control (6%)

III. Metformin till eGFR < 30

IV. Insulin early rather than late

Page 14: Management of Type 2 Diabetes

Key Points (3)4. BP aim <130/80.

I. Avoid Clinical Inertia

II. Often multiple medication required

III. <120 maybe harmful(Accord)

5. ACEI/ARB with microalbuminuria, whether or not hypertensive

6. Lipid control –

I. Consider satins early: Aim TC<4, TG<1.7

II. CV Guidelines

Page 15: Management of Type 2 Diabetes

Key Points (4)7. Diet/Exercise/Smoking Cessation essential in

management:

I. Diet/Exercise: Additional Benefit compared with most expensive new drugs if intensify diet/exercise.

8. Practice recalls for retinal screening/podiatry review/bloods/medical review

9. Specialist advice as required:

I. Case Conferencing, Phone, E-mail, combined Consults, Outpatients